Amgen’s $27.8bn Horizon Takeover Stipulates Biosimilar Restrictions
Biosimilar Restraint Part Of Litany Of New Considerations For Big Pharma Buyers
The FTC’s proposed consent order allowing Amgen to move ahead with its mammoth takeover of Horizon includes an interesting stipulation for industry – one involving biosimilars.
